Innate Pharma SA and partner Bristol-Myers Squibb Co. moved quickly to reassure investors that their cancer drug lirilumab remains on track for combo trialing in both solid and liquid tumors despite the drug's failure in the Phase II EffiKIR trial to hit its main endpoint of leukemia-free survival (LFS).
EffiKIR, sponsored by Innate to assess the efficacy of lirilumab as a single-agent maintenance for senior patients with AML in its first complete remission, found no statistically significant difference in LFS or other efficacy endpoints between the trial’s placebo arm and its two treatment arms
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?